New stock news | Lingke Pharmaceuticals' Hong Kong IPO prospectus invalid

Lingke Pharmaceutical (Zhejiang) Co., Ltd. (referred to as Lingke Pharmaceutical) submitted its Hong Kong IPO prospectus on December 1, 2025, which will expire on June 1, 2026, after 6 months. At the time of submission, CITIC SEC and ICBC International acted as joint sponsors. According to the prospectus, Lingke Pharmaceutical is a leading developer of innovative small molecule inhibitors for autoimmune and inflammatory diseases. The company's clinical pipeline mainly focuses on the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. As of the final practical date (November 26, 2025), the company's core products include LNK01001, a highly selective potential best-in-class second-generation JAK1 inhibitor, and LNK01004, a potential first-in-class third-generation soft pan-JAK inhibitor targeting autoimmune and inflammatory diseases. The company's key product LNK01006 is an advanced, highly selective and central nervous system-penetrating allosteric TYK2 inhibitor targeting central nervous system-related diseases. In addition, the company has established the innovative proprietary IsoNova protein degradation platform, which utilizes robust single molecule design to eliminate inactive isomers, providing clearer and better safety profiles. IsoNova also increases target selectivity and reduces off-target effects, expanding the range of degradable targets, including targets previously considered undruggable.